Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

CAPS Rating: 5 out of 5

The Company is engaged in the discovery and development of synthetic DNA and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, and asthma/allergies, and for use as vaccine adjuvants.

Recs

0
Player Avatar mbeleza (< 20) Submitted: 11/14/2007 5:56:55 AM : Underperform Start Price: $12.15 IDRA Score: +84.52

It´s at it's most

Featured Broker Partners


Advertisement